scholarly journals Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study

Eye ◽  
2011 ◽  
Vol 25 (2) ◽  
pp. 239-244 ◽  
Author(s):  
N J Shah ◽  
U N Shah
Keyword(s):  
Early Intervention ◽  
Pilot Study ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Central Retinal Vein Occlusion ◽  
Term Effect ◽  
Vein Occlusion ◽  
Long Term Effect ◽  
Central Retinal Vein

scholarly journals Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Qi Zhang ◽  
Yinfen Hou ◽  
Xiao Cao ◽  
Rongrong Zhang ◽  
Yinping Liu ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Layer Thickness ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Central Retinal Vein ◽  
Best Corrected Visual Acuity

Abstract Background The use of Spectral domain optical coherence tomography (SD-OCT) to evaluate the predictors of visual acuity-recovery in patients treated with conbercept for macular edema (ME) secondary to central retinal vein occlusion (CRVO) has rarely been seen. We collected 26 CRVO-ME patients with different OCT measures at 6 months follow-up to identify the factors that are most strongly correlated with the best-corrected visual acuity (BCVA) post-treatment in CRVO-ME patients treated with conbercept. Purpose To evaluate the effectiveness of intravitreal conbercept injections for the treatment of CRVO-ME and to determine the major predictors of best-corrected visual acuity (BCVA) post-treatment. Methods A retrospective study methodology was used. Twenty-six eyes from 26 patients with CRVO-ME were enrolled in the study. After an initial intravitreal injection of conbercept (0.5 mg/0.05 ml), monthly injections for up to 6 months were given following a 1 + PRN (pro re nata) regimen. Data collected at monthly intervals included measurements of the logMAR BCVA, central subfield thickness (CST), macular volume (MV), photoreceptor layer thickness (PLT), outer nuclear layer thickness (ONLT), and the disrupted ellipsoid zone (DEZ). The correlation between BCVA, before and after injections, and each of CST, MV, PLT, ONLT, DEZ was analyzed. Results The logMAR BCVA in months 3 and 6 post-injection was significantly improved relative to the baseline. In this same period the CST, MV, PLT, ONLT and DEZ were also significantly improved relative to the baseline. There was a negative correlation between PLT and logMAR BCVA at months 3 and 6 after treatment (r = − 0.549, P < 0.001; r = − 0.087, P < 0.001). Conclusion Intravitreal injection of conbercept is an effective treatment for CRVO-ME. With 6 months of follow-up, logMAR BCVA and CST, MV, PLT, ONLT, DEZ improved. PLT was negatively correlated with the visual function in CRVO-ME patients after conbercept treatment, which may be a predictor of vision recovery in patients with CRVO-ME.

scholarly journals Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial

2021 ◽  
Author(s):  
Chikako Hara ◽  
Motohiro Kamei ◽  
Hirokazu Sakaguchi ◽  
Nagakazu Matsumura ◽  
Susumu Sakimoto ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Protein C ◽  
Activated Protein C ◽  
Vein Occlusion ◽  
Central Retinal Vein

Abstract Purpose Our previous 1-year pilot study evaluated the efficacy of intravitreally injected activated protein C (APC) in 10 eyes with ischemic central retinal vein occlusion (CRVO). The reperfusion of the areas of retinal nonperfusion (RNP) exceeded 50% of the baseline in five (50%) eyes 1 year after the APC injection. The current study evaluated the long-term efficacy and safety of intravitreal APC. Methods The 10 eyes in the pilot study were included in this study. Other treatments were administered at the physicians’ discretion after the pilot study. We evaluated visual acuity (VA), central retinal thickness (CRT) and perfusion status, and adverse events and severity over the long term. Results The median follow-up was 60 months (range, 48–68 months). Compared with baseline, the post-treatment VA improved significantly (P < 0.001) from 1.39 to 1.06 logarithm of the minimum angle of resolution. The CRT improved significantly (P < 0.001) from 1090 to 195 μm at the last visit. The RNP areas decreased from an average 29.7 disc areas (DAs) at baseline to an average 16.5 DAs at the last examination (mean, 40 ± 6.5 months after the first APC treatment). No adverse events were related to intravitreal APC. Conclusion No complications were associated with intravitreal APC, the clinical course improved, and improved RNP was maintained for the long term, suggesting that intravitreal APC may be an alternative treatment for CRVO.

Sign in / Sign up

Export Citation Format

Share Document